RECRO PHARMA INC's ticker is REPH and the CUSIP is 75629F109. A total of 76 filers reported holding RECRO PHARMA INC in Q1 2021. The put-call ratio across all filers is 0.29 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $487,000 | -23.2% | 300,427 | -62.5% | 0.00% | 0.0% |
Q2 2022 | $634,000 | -58.9% | 800,661 | -6.8% | 0.00% | -66.7% |
Q1 2022 | $1,544,000 | -1.3% | 859,039 | -6.2% | 0.00% | +50.0% |
Q4 2021 | $1,564,000 | +56.1% | 915,745 | +87.9% | 0.00% | 0.0% |
Q3 2021 | $1,002,000 | -21.5% | 487,270 | -12.0% | 0.00% | 0.0% |
Q2 2021 | $1,276,000 | -19.5% | 553,592 | -2.7% | 0.00% | -33.3% |
Q1 2021 | $1,586,000 | -1.7% | 569,022 | +0.3% | 0.00% | 0.0% |
Q4 2020 | $1,614,000 | +1693.3% | 567,258 | +1200.0% | 0.00% | – |
Q3 2020 | $90,000 | -89.1% | 43,634 | -76.1% | 0.00% | -100.0% |
Q2 2020 | $828,000 | +114.5% | 182,406 | +284.5% | 0.00% | +100.0% |
Q1 2020 | $386,000 | -81.1% | 47,438 | -57.4% | 0.00% | -75.0% |
Q4 2019 | $2,043,000 | +391.1% | 111,459 | +196.9% | 0.00% | +300.0% |
Q3 2019 | $416,000 | +766.7% | 37,544 | +674.4% | 0.00% | – |
Q2 2019 | $48,000 | +29.7% | 4,848 | -34.9% | 0.00% | – |
Q2 2018 | $37,000 | +117.6% | 7,443 | +396.2% | 0.00% | – |
Q1 2018 | $17,000 | – | 1,500 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Engine Capital Management, LP | 872,494 | $6,195,000 | 3.64% |
Newtyn Management, LLC | 1,600,000 | $11,360,000 | 2.22% |
Broadfin Capital, LLC | 2,048,025 | $14,541,000 | 1.91% |
Balter Liquid Alternatives, LLC | 92,167 | $654,000 | 0.45% |
ESSEX INVESTMENT MANAGEMENT CO LLC | 515,414 | $3,660,000 | 0.29% |
JT Stratford LLC | 45,367 | $322,000 | 0.21% |
Opus Point Partners Management, LLC | 11,353 | $81,000 | 0.18% |
Alyeska Investment Group, L.P. | 964,000 | $6,844,000 | 0.10% |
KENNEDY CAPITAL MANAGEMENT LLC | 500,625 | $3,554,000 | 0.09% |
Monarch Partners Asset Management LLC | 55,857 | $397,000 | 0.06% |